News
IOVA
3.430
-0.58%
-0.020
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help
Seeking Alpha · 3d ago
Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
TipRanks · 4d ago
Weekly Report: what happened at IOVA last week (0323-0327)?
Weekly Report · 4d ago
Weekly Report: what happened at IOVA last week (0316-0320)?
Weekly Report · 03/23 09:08
Iovance Biotherapeutics Announces Upcoming Board Member Retirement
TipRanks · 03/20 21:37
Iovance Biotherapeutics grants 3,400 inducement stock options at USD 3.87 exercise price
Reuters · 03/20 21:15
Iovance director Wendy Yarno to retire from board in June 2026
Reuters · 03/20 21:01
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Barchart · 03/20 16:15
Weekly Report: what happened at IOVA last week (0309-0313)?
Weekly Report · 03/16 09:08
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 03/12 12:02
Weekly Report: what happened at IOVA last week (0302-0306)?
Weekly Report · 03/09 09:08
Iovance Biotherapeutics call volume above normal and directionally bullish
TipRanks · 03/06 19:45
What's Going On With Iovance Biotherapeutics Stock On Friday?
Benzinga · 03/06 18:06
Iovance Biotherapeutics Is Maintained at Neutral by UBS
Dow Jones · 03/05 15:14
UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $4
Benzinga · 03/05 15:04
IOVANCE BIOTHERAPEUTICS INC <IOVA.O>: UBS RAISES TARGET PRICE TO $4 FROM $2
Reuters · 03/05 14:41
Iovance Biotherapeutics price target raised to $4 from $2 at UBS
TipRanks · 03/05 12:39
U.S. RESEARCH ROUNDUP-Broadcom, CNX Resources, Veeva Systems
Reuters · 03/05 07:16
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
Seeking Alpha · 03/04 17:17
Iovance Biotherapeutics Signals Strong Momentum In Earnings
TipRanks · 03/04 00:25
More
Webull provides a variety of real-time IOVA stock news. You can receive the latest news about Iovance Biotherp through multiple platforms. This information may help you make smarter investment decisions.
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.